Background: Although anterior cruciate ligament (ACL) reconstruction is the treatment gold standard for ACL injury, it does not reduce the risk of posttraumatic osteoarthritis. Therefore, new treatments that minimize this postoperative complication are of interest. Bioenhanced ACL repair, in which a bioactive scaffold is used to stimulate healing of an ACL transection, has shown considerable promise in short-term studies. The long-term results of this technique and the effects of the bioenhancement on the articular cartilage have not been previously evaluated in a large animal model.
Patients presenting with an anterior cruciate ligament (ACL) tear are at high risk for developing posttraumatic osteoarthritis regardless of whether they undergo ACL reconstruction surgery. This risk has been reported to be as high as 78% within 14 years of injury. 38 The reason for such a high risk is unknown, but it is likely attributable to the inflammatory response, impact damage, abnormal joint kinematics, and abnormal stresses within the cartilage that predispose the menisci and articular surfaces to premature breakdown. 2, 7, 10 Because the rates of graft failure and posttraumatic osteoarthritis are significant problems for patients with ACL injury, there is a need to develop novel approaches to improve outcomes. One such approach is bioenhanced ACL repair, in which a bioactive scaffold is placed between the torn ends of the ligament to stimulate healing with suture repair. 12, 13, 18, 21, 22, [24] [25] [26] [27] 37 The bioactive scaffold, which is based on the extracellular matrix proteins found in the normal ACL, activates the platelets in the patient's own blood to release anabolic growth factors including platelet-derived growth factor (PDGF), fibroblast growth factor-2 (FGF-2), and transforming growth factor-b (TGF-b) into the wound site ( Figure 1) . 14, 17, 28 The bioenhanced ACL repair technique has shown efficacy in animal models as the structural properties of the repaired ligament are similar to those of an ACL reconstruction graft after 3 months. 37 Another approach is bioenhanced ACL reconstruction ( Figure 1 ), in which a similar bioactive scaffold is placed around an autograft or allograft to enhance healing. 13, 33 Preliminary short-term data have indicated that the scaffold-platelet composite can stimulate healing of ACL autografts and allografts in preclinical models. 13, 33 The long-term results of bioenhanced ACL repair and reconstruction and the effects of the bioenhancement on the articular cartilage have not been evaluated.
It has been previously demonstrated that the use of a bioactive scaffold can significantly improve the results of a traditional ACL suture repair 18 and that the structural properties of the bioenhanced ACL repairs are equivalent to those of conventional ACL reconstruction in the porcine model at 3 months. 37 The first aim of this study was to determine whether the results previously reported at 3 months would persist 6 and 12 months after surgery. The second aim was to determine whether the bioactive scaffold would reduce macroscopic cartilage damage after ACL injury and treatment. We hypothesized that the structural properties of the ligament after bioenhanced ACL repair would be equal to the structural properties after bioenhanced ACL reconstruction and conventional ACL reconstruction and superior to those after untreated ACL transection. We also hypothesized that the macroscopic cartilage damage after bioenhanced ACL repair would be equal to bioenhanced ACL reconstruction and less than conventional ACL reconstruction and untreated ACL transection.
MATERIALS AND METHODS

Study Design
Approvals were obtained from the institutional animal care and use committee. A total of 64 Yucatan mini-pigs in late adolescence (with closed tibial and femoral physes) (age [mean 6 SD], 15.0 6 0.95 months; weight, 58.6 6 7.9 kg] underwent ACL transection and were randomized to 1 of 4 experimental groups: (1) no treatment, (2) conventional ACL reconstruction with bone-patellar tendon-bone (BPTB) allograft, 37 (3) bioenhanced ACL reconstruction with BPTB allograft and a bioactive scaffold, 13 and (4) bioenhanced ACL repair with a bioactive scaffold of the same material and sutures ( Figure 1) . 25 Half of the animals within each treatment group were allowed to heal for 6 and 12 months, respectively.
Preparation of the Extracellular Matrix Scaffold
The bioactive scaffolds (MIACH, Boston Children's Hospital, Boston, Massachusetts) were manufactured as previously described. 25 A slurry of extracellular matrix proteins was produced by solubilizing bovine connective tissue. The collagen concentration was adjusted to a minimum of 10 mg/mL and lyophilized. For the bioenhanced ACL reconstruction group, the scaffold was a porous, hollow cylinder with an outer diameter of 22 mm, an inner diameter of 10 mm, and a length of 30 mm. 25 For the bioenhanced ACL repair group, the scaffolds were solid porous cylinders 22 mm in diameter and 30 mm long. 13 All scaffolds were stored at 220°C until the day of surgery. When implanted in the joint, the scaffolds were bioactivated with the addition of blood containing platelets.
Surgical Technique: ACL Transection
A medial arthrotomy was created and the fat pad partially resected to expose the ACL. The ACL was cut between the proximal and middle thirds of the ligament. A Lachman Figure 1 . Four treatment groups were evaluated in this study: (A) ACL transection, (B) conventional ACL reconstruction, (C) bioenhanced ACL reconstruction, and (D) bioenhanced ACL repair.
test was performed to verify complete transection. The knee was then irrigated with 500 mL of normal saline. For those animals assigned to receive no treatment, the incision was then closed, 37 and the ligament was allowed to heal naturally.
Surgical Technique: ACL Reconstruction and Bioenhanced ACL Reconstruction
After ACL transection in the animals assigned to conventional ACL reconstruction, surgery with fresh-frozen BPTB allografts harvested from age-, weight-, and sexmatched donors was performed as previously described. 13 The entire patellar tendon (~10 mm in width) was used for the soft tissue portion of the graft while the bone plugs were trimmed to 7 mm diameter. Femoral graft fixation was achieved with a 6 3 20-mm bioabsorbable interference screw (Biosure, Smith & Nephew, Andover, Massachusetts). The graft was manually preconditioned in tension 20 times and firmly tensioned with the knee in maximal extension (~30°for the pig). The distal block was secured in the tibia with a second 6-mm interference screw backed up with an extracortical tibial button. For the animals in the bioenhanced ACL reconstruction group, the same ACL reconstruction procedure was performed; however, just after femoral graft fixation, the hollow cylindrical extracellular matrix-based scaffold was threaded onto the graft and positioned to cover the intraarticular soft tissue portion. The distal bone plug was seated retrograde into the tibial tunnel and fixed to the tibia with a 6-mm interference screw backed with an extracortical tibial button. Three milliliters of autologous blood was used to saturate and activate the scaffold in situ. The scaffold-blood composite was confined within the intercondylar notch and did not extend over the articular surfaces. The composite was allowed to set for a minimum of 10 minutes before completing the surgical procedure.
Surgical Technique: Bioenhanced ACL Repair
For the animals in the bioenhanced ACL repair group, the repair was performed as previously described. 25 In brief, an Endobutton carrying 3 looped sutures was passed through a 4-mm femoral tunnel and flipped. Two of the sutures were threaded through the scaffold, into a predrilled tibial tunnel and fixed extracortically with a button while the knee was in maximum extension. The remaining suture was tied to a Kessler suture of No. 1 Vicryl (Ethicon, Somerville, New Jersey), which had been placed in the tibial stump of the ACL (Figure 1) . 11 Three millimeters of autologous blood was used to saturate and activate the scaffold. The scaffold-blood composite was allowed to set for a minimum of 10 minutes before completion.
All incisions were closed in layers. 37 After surgery, all animals were housed for 4 weeks in individualized pens and were then shipped to a farm for long-term care (Coyote Consulting Corp Inc, Douglas, Massachusetts). After 6 and 12 months of healing, the animals were sacrificed and the limbs were harvested and immediately frozen at 220°C until mechanical testing.
Biomechanical Testing
The knees were prepared for biomechanical testing as previously described. 13 The biomechanical testing procedures (ie, anteroposterior [AP] knee laxity, structural properties) were performed by use of a servohydraulic load frame and custom fixtures (MTS Systems Corporation, Eden Prairie, Minnesota). 13 All investigators were blinded to the treatment group during preparation and testing. The AP knee laxity was measured with the joint capsule intact at 30°, 60°, and 90°of flexion by applying anterior-posterior directed shear loads of 640 N at 0.0833 Hz for 12 cycles. 11 The structural properties of the ligaments and grafts were then determined by tensile failure testing after the capsule and other ligaments were removed. 18 The femur was lowered until a 5-N compression load was applied followed by a tensile ramp of 20 mm/min. The load-displacement data were recorded, and the linear stiffness, yield, and failure loads were calculated. 19 Before tensile testing, the cross-sectional areas of the healing ACLs or grafts were measured with Vernier calipers. The cross-sectional areas were estimated under the assumption that the ligament cross-section was elliptical.
Ligament Histological Characteristics
After mechanical testing, the knees were cut in the sagittal plane through the ACL tissue (intact, repaired, or graft). All tissue was fixed in formalin, decalcified (DELTA-Cal, Delta Products Group, Aurora, Illinois), and sagittally cut through the ACL tissue mass. The knee sections were dehydrated, embedded in paraffin, and microtomed into 7-mm sections. These sections were mounted on slides (Corning 75 3 50-mm Plain Microscope Slides, Corning Inc, Corning, New York) and stored at 4°C until staining with hematoxylin and eosin or a-smooth muscle actin antibodies. Hematoxylin and eosin staining was used to determine cell density and collagen formation, whereas asmooth muscle actin immunohistochemistry was used to determine vascularity. Qualitative analyses of the cell density and vascular density were performed by an observer blinded to the treatment groups and time point of the photomicrographs.
Macroscopic Cartilage Assessment
After tissue harvest, the length and width of all visible lesions in 4 regions of interest (ie, the medial and lateral femoral condyles and the medial and lateral tibial plateaus) of the surgically treated and contralateral ACL-intact knees were measured using calipers following the application of india ink to highlight surface irregularities. Lesion areas were estimated assuming elliptical fits. The lesion areas for each region were summed to give the total lesion area for each knee joint. Two independent examiners, who were blinded to the leg and treatment group, performed all measurements. The values for each examiner were averaged. In addition, the specimens were scored using a commonly used macroscopic scoring method (see the Appendix, available online at http://ajsm.sagepub.com/supplemental). 32 
Statistical Analysis
Generalized estimating equations were used to model the structural properties, cross-sectional areas, AP knee laxities, total cartilage lesion areas, and macroscopic cartilage scores. Models contained main effects and all interactions involving experimental condition, limb, and postsurgical time of sacrifice. The nesting of surgical and intact limbs within animals was modeled as having correlated error by use of a heterogeneous compound symmetry variance-covariance matrix, block diagonal by group. The distribution and corresponding link function were chosen based on measurement scaling and model residual diagnostics. When no clear winner emerged, conventional treatment was chosen. Classic sandwich estimation was further used to adjust for model misspecification. Hypotheses were tested as orthogonal linear estimates and adjusted (P adj ) to maintain alpha at .05 using the Holm test. The initial family of comparisons between treatment groups determined whether the contralateral limbs were affected by experimental condition, which would invalidate their use for normalization of surgical limbs. It was determined that normalization was not appropriate for analyzing the cartilage lesion/scoring data because the data for the uninjured knee were dependent on the animal's treatment group assignment.
RESULTS
Animal Welfare
One animal died on induction of anesthesia. Full weightbearing status was achieved within 48 to 72 hours for all other animals. Two animals (both in the ACL transected group) developed subcutaneous abscesses near the jaw that were treated with short-term oral antibiotics, and an animal in the bioenhanced ACL reconstruction group (6 month) died of a respiratory infection within 1 week of the planned sacrifice date. These 3 animals were included in the study as there was no visual evidence of joint synovitis at the time of dissection. One animal in the bioenhanced repair group (12 months) was shipped to the external facility at 2 weeks rather than 4 weeks postoperatively, a deviation in the postoperative rehabilitation, and another in the ACL reconstruction group (6 months) was sacrificed at 2 rather than 6 months because of identification error. Both of these animals were excluded from the analysis. At 6 months, the total number of animals in each group was 8, except for the ACL transected group (n = 7). At 12 months, the total number of animals in each group was 8, except for the ACL transected group (n = 7) and bioenhanced ACL repair group (n = 7).
Ligament Biomechanics: Structural Properties
The mean structural property data for the surgical and control knees at 6 and 12 months are presented in Table 1 . At 6 months, the mean normalized linear stiffness values between the 3 surgical treatment groups were not significantly different from each other (P adj . .2890; Figure 2A ). After 12 months of healing, the normalized linear stiffness values for the 3 treatment groups were all significantly greater than values for the ACL transected group (P adj \ .0005; Figure 2A ). The normalized linear stiffness values for the ligament or graft after bioenhanced ACL repair, bioenhanced ACL reconstruction, and conventional ACL reconstruction were equivalent to each other (P adj . .5746). The same overall patterns across groups were observed in the yield load ( Figure 2B ) and maximum failure load ( Figure  2C ) data sets. The cross-sectional areas of the bioenhanced ACL repairs and both grafts were highly variable and not significantly different (P . .14; Table 1 ).
Knee Biomechanics: AP Laxity
The AP laxity data for both the surgical and contralateral uninjured knees are provided in Table 1 . At 6 months, the ratios (surgical/intact) of mean AP laxity values at 30°of flexion were similar between the ACL reconstructed, bioenhanced ACL reconstruction, and bioenhanced ACL repair groups (P adj . .2801). Only the mean AP laxity value for the ACL reconstructed group was significantly lower than that for the ACL transected group (P adj = .0433). After 12 months of healing, the mean AP laxity values at 30°of flexion for all 3 surgical treatment groups were significantly lower than that for the ACL transected group (P adj \ .0269). No other significant differences in AP laxity were found.
Ligament Histological Characteristics
The intact ACLs had relatively sparse distributions of cells and vasculature (Figure 3 ). Six months after surgery, the ligament repair and reconstruction groups had much greater cellularity throughout the ACL tissue (Figure 3) . The hypercellularity in all groups decreased by 12 months, but the treatment groups still appeared to have a greater number of cells within the tissue than the intact ACL knee. In terms of vascularity, the bioenhanced ACL reconstructed group had a pattern similar to that seen in the intact ACL at both 6 and 12 months, whereas the bioenhanced repair group and the ACL reconstruction group were hypervascular at both time points.
Cartilage Assessment
There were no significant differences in the lesion areas of the surgical limbs between the 4 experimental groups at 6 months postoperatively (P adj . .380; Figure 4) . However, at 12 months, the mean lesion area for the bioenhanced ACL repair knees was significantly less than that for the ACL transected knees (P adj = .0017) and the bioenhanced ACL reconstructed knees (P adj = .0198). There was a strong trend indicating that the lesion areas in the bioenhanced ACL repaired knees were less than those in the ACL reconstructed knees (P adj = .068). There were no other statistical differences (P adj . .6821) 12 months postoperatively. Comparisons between the total macroscopic scores between groups and knees followed trends similar to those of the lesion area measurements (see Appendix Figure S1 , available online).
DISCUSSION
The results support the first hypothesis that the structural properties of the ligament after bioenhanced ACL repair were similar to those after bioenhanced ACL reconstruction and conventional ACL reconstruction and superior to those after untreated ACL transection after 12 months of healing. The linear stiffness and yield load values for all 3 surgically treated groups were similar at both 6 and 12 months. Although there was no difference between the untreated ACL transected ligaments and the bioenhanced ACL repaired ligaments at 6 months, the yield load of the bioenhanced repair procedure continued to improve and became significantly different from the transection control at 12 months (Figure 2 ). On average, the mean AP laxity values of the surgically treated limbs were greater than those of the contralateral uninjured limb ( Table 1) . The AP laxity values at 30°of flexion for the surgically treated In contrast, all 3 experimental groups had a much higher cell density throughout the ACL tissue after 6 months (B, C, and D). The hypercellularity in all groups decreased by 12 months, but the experimental groups still appeared to have a greater number of cells within the tissue than the intact ACL (E, F, and G). The bioenhanced ACL reconstruction (BE-ACLR) group had a vascularity pattern similar to that seen in the intact ACL at both 6 and 12 months (J and M), whereas the BE-repair and ACLR groups were hypervascular at both time points (I, K, L, and N) . ACLT, ACL transection. Figure 4 . The mean total lesion areas for the 4 experimental groups at 6 and 12 months for the surgical and the ACL intact knees. The mean data are plotted with the 95% confidence intervals. Means that are significantly different after Holm adjustment are highlighted with *P adj \ .05 or **P adj \ .01. It was not appropriate to normalize the findings to the contralateral knee because there were significant differences in the contralateral knee between treatment groups at both 6 and 12 months. ACLT, anterior cruciate ligament (ACL) transection; ACLR, ACL reconstruction; BE-ACLR, bioenhanced ACL reconstruction; BE-repair, bioenhanced ACL repair. Note the damage to the medial femoral condyle in the untreated knee, ACL-reconstructed knee, and the bioenhanced ACL-reconstructed knee (black arrows) and the lack of damage to the medial femoral condyle in the bioenhanced ACL-repair knee (white arrow).
knees were significantly less than those for the untreated ACL transected limbs at 12 months. However, no other differences in AP laxity were observed.
The results partially support our second hypothesis that the macroscopic cartilage damage of the tibiofemoral joint after bioenhanced ACL repair was less than that after untreated ACL transection, and there was a strong trend for such damage to be less than that after conventional ACL reconstruction (P = .068) at 12 months (Figures 4  and 5 ). Both ACL transection and ACL reconstruction resulted in increased chondral damage over time, a finding previously reported in human patients. 38 However, our results did not support the portion of the hypothesis related to bioenhanced ACL reconstruction, where the macroscopic cartilage damage was greater than expected and not significantly different from the damage of ACL reconstructed or ACL transected knees. No differences in macroscopic cartilage damage were observed in the operative knees between treatment groups at 6 months. This finding may reflect the longer time period required to allow progression of the damage that is measurable with gross macroscopic techniques.
Furthermore, macroscopic cartilage damage was evident in the contralateral uninjured knees ( Figure 4B ). The macroscopic cartilage scores in the contralateral knee of the bioenhanced ACL reconstructed animals were significantly greater than the scores for the other treatment groups. Because the animals were randomized to the treatment groups, it is unlikely that this effect was due to different baseline conditions between treatments. The treatment group differences in the contralateral knee make its use as a normal control questionable in studies that evaluate posttraumatic cartilage integrity, at least in the porcine model. This effect has been noted in other large animal models. 4 In future studies it would be valuable to include a sham control group to isolate the source of this contralateral effect.
The bioenhanced ACL repair technique resulted in protection of the articular cartilage in the porcine model. The mechanism behind this is unknown and is the focus of ongoing research. It is well known that joint kinematics, and hence cartilage loading, are altered after ACL injury, 2 which in turn could negatively affect cartilage metabolism. Although ACL reconstruction and repair procedures attempt to restore joint kinematics, evidence suggests that this attempt is not completely successful. 3, 30, 35 Examination of the AP laxity values from the 4 experimental groups demonstrates that normal kinematics were not restored in the present study (Table 1) . Other factors besides joint kinematics must therefore play a role in chondroprotection following bioenhanced ACL repair.
It seems reasonable to assume that alteration in joint inflammation and subsequent release of degradative enzymes after injury and after surgery could preserve articular cartilage integrity. It is possible that the bioactive scaffold containing the platelets to stimulate ligament healing in bioenhanced ACL repair also affected cartilage biological functions. In vitro studies have shown that growth factors released from platelets stimulate chondrocyte proliferation and biosynthesis of cartilage extracellular matrix 1, 8, 34 and diminish deleterious effects of interleukin-1b on human arthritic chondrocytes. 36 Recently, an antigen-induced porcine arthritis model revealed that the intra-articular injection of platelets reduced several inflammatory cytokines in both cartilage and synovial fluid, reduced synovial hypertrophy, and increased the synthesis of proteoglycan and collagen type II. 20 These data suggest that the chondroprotection after the bioenhanced ACL repair procedure may be due, at least in part, to the activation of platelets in the bioactive scaffold. However, the bioenhanced ACL reconstruction procedure did not have this effect. Future research will be aimed at figuring out the mechanisms to explain these divergent findings.
The placement of the bioactive scaffold during surgical ACL repair resulted in a ligament that was biomechanically similar to the graft after ACL reconstruction in the late adolescent model. These data support previous findings in the juvenile model where bioenhanced ACL repair was also similar to ACL reconstruction. 37 However, the structural properties of the bioenhanced ACL reconstruction group were not significantly different from conventional ACL reconstruction in the late adolescent model. This is contrary to previous findings in juvenile pigs at 3 months 13 but is supported by those found in adult goats 6 weeks postoperatively. 33 A likely explanation is that the healing response in late adolescent and adult animals is diminished when compared with juvenile animals 25 ; thus, the effects of bioenhanced ACL reconstruction may be less obvious in older animals.
The structural properties after ACL reconstruction and bioenhanced ACL reconstruction were not significantly different from one another after 12 months of healing, with the maximum loads reaching 65% and 67% of the contralateral knee, respectively. Likewise, the linear stiffness values reached 69% and 77% of the contralateral knee, respectively. The structural properties obtained in our study are similar to or better than those previously reported for patellar tendon grafts in ovine and caprine models after 12 months. 6, 15 Complete restoration of the structural properties of the ACL was not expected because other animal models of ACL reconstruction have shown that the histological, gross morphometric, and biomechanical properties of healing ACL grafts are inferior to those of the ACL intact knee. 9, 16, 31 The pig model has some limitations common to all animal models of ACL surgery. The pig is a quadruped and therefore does not fully represent the human condition. Postoperative rehabilitation is particularly difficult to control in any animal model. Nonetheless, the porcine model has specific advantages for this study because the porcine platelet profile and wound healing characteristics more closely match those of the human when compared with those of the goat or sheep. 23, 29 The porcine model is also well suited for this application given that many anatomic and biomechanical similarities between the pig and human knee have been noted. 5, 29, 39 There are other limitations to consider. The ACL injury was created by use of a scalpel to transect the ligament in its midsubstance. It is possible that a more frayed ligament would heal differently with bioenhanced ACL repair. For the ACL reconstructed treatment groups, fresh-frozen allografts were used instead of autografts. In the porcine model, harvesting the patellar tendon graft would compromise the extensor mechanism, and soft tissue autografts are not readily available. It is possible that autografts would provide better outcomes. Nonetheless, the structural properties of allografts in our pig model were similar to those reported for autografts in other quadruped models. 9, 16, 31 Finally, it would have been advantageous to include a sham control group (ie, no ACL transection) because treatment group assignment affected the cartilage integrity of the contralateral knee.
In this paper, we compared the performance of conventional ACL reconstruction, bioenhanced ACL reconstruction, and bioenhanced primary repair at time points up to a year after surgery using a late adolescent animal model. Although none of the treatment methods were able to restore normal AP laxity of the porcine knee, all treatments had similar biomechanical performance with 1 year of healing. Furthermore, the group treated with bioenhanced ACL repair had significantly less posttraumatic osteoarthritis than did the other experimental groups. The biomechanical similarities and improved cartilage outcomes for bioenhanced repair suggest that further work to translate this technique to clinical trial may be warranted.
